References

Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis

10.1016/j.ejca.2022.09.031 · 2022 · External reference

Facts and Hopes in Using Omics to Advance Combined Immunotherapy Strategies

10.1158/1078-0432.ccr-22-2241 · 2024 · External reference

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

10.1200/jco.21.02885 · 2023 · External reference

Addressing cancer's grand challenges

10.1038/d41573-020-00202-0 · 2020 · External reference

Therapeutic targeting of regulatory T cells in cancer

10.1016/j.trecan.2022.06.008 · 2022 · External reference

FOXP3+ regulatory T cells in the human immune system

10.1038/nri2785 · 2010 · External reference

PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis

10.1080/2162402x.2020.1729299 · 2020 · External reference

Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy

10.1186/s13287-022-02829-9 · 2022 · External reference

Tumor-initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice

10.1172/jci180893 · 2025 · External reference

Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies

10.1016/j.immuni.2025.03.021 · 2025 · External reference

CD25-T(reg)-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity

10.1038/s43018-020-00133-0 · 2020 · External reference

CD103(+) regulatory T cells underlie resistance to radio-immunotherapy and impair CD8(+) T cell activation in glioblastoma

10.1038/s43018-023-00547-6 · 2023 · External reference

Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity

10.1016/j.immuni.2024.07.010 · 2024 · External reference

FOXP3(+) regulatory T cell perturbation mediated by the IFNγ-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity

10.1038/s41467-023-44391-9 · 2024 · External reference

Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling

10.1038/s41467-024-54874-y · 2024 · External reference

Increased SOAT2 expression in aged regulatory T cells is associated with altered cholesterol metabolism and reduced anti-tumor immunity

10.1038/s41467-025-56002-w · 2025 · External reference

A CD25×TIGIT bispecific antibody induces anti-tumor activity through selective intratumoral Treg cell depletion

10.1016/j.ymthe.2024.09.010 · 2024 · External reference

Integrated NLRP3, AIM2, NLRC4, Pyrin inflammasome activation and assembly drive PANoptosis

10.1038/s41423-023-01107-9 · 2023 · External reference

A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseases

10.1016/j.cell.2023.04.025 · 2023 · External reference

AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model

10.1158/1535-7163.mct-05-0310 · 2006 · External reference

AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA

10.1038/nature07710 · 2009 · External reference

An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome

10.1038/ni.1702 · 2009 · External reference

Immunobiology and structural biology of AIM2 inflammasome

10.1016/j.mam.2020.100869 · 2020 · External reference

AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC

10.1038/nature07725 · 2009 · External reference

Inflammasome: structure, biological functions, and therapeutic targets

10.1002/mco2.391 · 2023 · External reference

Molecular mechanisms of emerging inflammasome complexes and their activation and signaling in inflammation and pyroptosis

10.1111/imr.13406 · 2025 · External reference

Absent in Melanoma 2 (AIM2) Regulates the Stability of Regulatory T Cells

10.3390/ijms23042230 · 2022 · External reference

AIM2 in regulatory T cells restrains autoimmune diseases

10.1038/s41586-021-03231-w · 2021 · External reference

Interruption of the intratumor CD8(+) T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy

10.1016/j.ccell.2024.05.013 · 2024 · External reference

PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

10.1073/pnas.1822001116 · 2019 · External reference

Myeloid-derived suppressor cells in cancer and cancer therapy

10.1038/s41571-023-00846-y · 2024 · External reference

Succinate-loaded tumor cell-derived microparticles reprogram tumor-associated macrophage metabolism

10.1126/scitranslmed.adr4458 · 2025 · External reference

AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma

10.1084/jem.20200962 · 2021 · External reference

Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation

2022 · External reference

Targeting the metabolism of tumor-infiltrating regulatory T cells

10.1016/j.it.2023.06.001 · 2023 · External reference

Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review

10.1186/s12967-024-05104-y · 2024 · External reference

EFLA 945 restricts AIM2 inflammasome activation by preventing DNA entry for psoriasis treatment

10.1016/j.cyto.2019.154951 · 2020 · External reference

TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of AIM2

10.1016/j.celrep.2023.113231 · 2023 · External reference

NLRP3 Attenuates Intraocular Inflammation by Inhibiting AIM2-Mediated Pyroptosis Through the Phosphorylated Salt-Inducible Kinase 1/Sterol Regulatory Element Binding Transcription Factor 1 Pathway

10.1002/art.42420 · 2023 · External reference

Overexpressed CD44 is associated with B-cell activation via the HA-CD44-AIM2 pathway in lupus B cells

10.1016/j.clim.2023.109710 · 2023 · External reference

Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer

10.1146/annurev-immunol-082223-044122 · 2025 · External reference

CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool

10.1158/2159-8290.cd-23-1263 · 2024 · External reference

Soluble Tim-3 serves as a tumor prognostic marker and therapeutic target for CD8(+) T cell exhaustion and anti-PD-1 resistance

2024 · External reference

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses

10.1016/j.immuni.2022.02.005 · 2022 · External reference

Spatial profiling technologies illuminate the tumor microenvironment

10.1016/j.ccell.2023.01.010 · 2023 · External reference

Murine regulatory T cells utilize granzyme B to promote tumor metastasis

10.1007/s00262-023-03410-w · 2023 · External reference

Metabolism, metabolites, and macrophages in cancer

10.1186/s13045-023-01478-6 · 2023 · External reference

Deciphering the performance of macrophages in tumour microenvironment: a call for precision immunotherapy

10.1186/s13045-024-01559-0 · 2024 · External reference

Targeting lipid metabolism of macrophages: A new strategy for tumor therapy

10.1016/j.jare.2024.02.009 · 2025 · External reference

Hand in hand to successful immunotherapy: CD8(+) T cells and M1-like macrophages swap the baton

10.1016/j.ccell.2024.05.012 · 2024 · External reference

Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy

10.1016/j.ccell.2024.04.011 · 2024 · External reference